US 11,999,753 B2Granted

Tetrahydropyridopyrimidine pan-KRas inhibitors

AssigneeMirati Therapeutics, Inc.

InventorsXiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith

Life of this patent

Estimating the term…

Abstract

The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Claims5

Dependent claims

A compound selected from:

and a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 17/553,224Filed 16 Dec 2021 · us provisional application
Priority: 16 Dec 2020
Published: US 2022/0194961 A123 Jun 2022
Granted: 4 Jun 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07D 519/00
Heterocyclic compounds containing more than one system of two or more relevant
A61P 35/00
Antineoplastic agents
C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
C07D
Heterocyclic compounds

Family

Application63/126,350Us provisional application · filed 16 Dec 2020
Application63/158,119Us provisional application · filed 8 Mar 2021
Application63/164,345Us provisional application · filed 22 Mar 2021
US 2022/0194961 A1Pre-grant publication · published 23 Jun 2022
US 11,999,753 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results